Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics, National Institutes of Health, MDRNA, University of Michigan, RXi Pharmaceuticals

Premium
Rosetta, NIH to Collaborate on Identifying miRNAs Involved in HIV
 
Rosetta Genomics this week said it will work with the National Institutes of Health to discover microRNAs that may be involved in the viral replication of HIV.

Rosetta said it will use its microRNA-detection and quantification technologies, as well as publicly known human and viral microRNAs, to determine the role miRNAs plan in HIV replication and whether they may be used as potential novel drug targets for the disease.

Specific terms of the deal were not released.
 

 
MDRNA Licenses Peptide Delivery Tech from University of Michigan
 
MDRNA said this week that it has exclusively acquired intellectual property from the University of Michigan covering cationic peptides for enhanced delivery of nucleic acids.
Terms of the arrangement were not disclosed.
 
“The small cationic peptides covered by the University of Michigan intellectual property are capable of forming stable siRNA nanoparticle complexes, thereby protecting the siRNA while increasing the efficiency and efficacy of the formulations,” the company said. “In addition, they can also enhance endosomal release. … Results to date have demonstrated both enhanced knockdown of target proteins in vivo, as well as improvement in delivery efficiency.”
 

 
RXi Q2 Losses Drop as R&D Costs Shrink
 
RXi Pharmaceuticals last week reported a decline in its second-quarter net loss amid a drop in research and development spending.
 
In the quarter, RXi’s net loss slipped to $4.3 million, or $0.34 per share, from a year-ago loss of $4.8 million, or $0.42 per share.
 
R&D costs in the quarter dropped to $2.8 million from $3.8 million a year earlier, while general and administrative expenses rose about $500,000 to $1.6 million, reflecting the costs associated with RXi’s operating as a public company following its spin out from CytRx (see RNAi News, 3/13/2008).
 
As of June 30, RXi had cash, cash equivalents, and short-term investments totaling $15.1 million.